From: Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
Antibody | Half-Maximum Lysis [ng/ml] Maximum Lysis [Percent] | Mean Half-Maximum Lysis [ng/ml] ± S.D. | ||||
---|---|---|---|---|---|---|
Donor | ||||||
1 | 2 | 3 | 4 | 5 | ||
Edrecolomab | 49 | n.d. | 21 | 917 | 68 | 264 ± 436 |
40% | n.d. | 24% | 37% | 16% | ||
Chimeric Edrecolomab | 277 | 1.910 | 69 | 515 | 596 | 671 ± 721 |
84% | 43% | 19% | 94% | 44% | ||
3622W94 | 4.5 | 102 | 2.0 | 4.9 | 79 | 38 ± 48 |
77% | 42% | 43% | 82% | 46% | ||
ING-1 | 2.6 | 48 | 0.9 | 8.2 | 10 | 14 ± 19 |
90% | 47% | 23% | 78% | 54% | ||
Adecatumumab | 50 | 537 | 11 | 100 | 176 | 175 ± 211 |
86% | 39% | 27% | 76% | 53% |